MX2008010767A - Metodo para tratar celulitis. - Google Patents
Metodo para tratar celulitis.Info
- Publication number
- MX2008010767A MX2008010767A MX2008010767A MX2008010767A MX2008010767A MX 2008010767 A MX2008010767 A MX 2008010767A MX 2008010767 A MX2008010767 A MX 2008010767A MX 2008010767 A MX2008010767 A MX 2008010767A MX 2008010767 A MX2008010767 A MX 2008010767A
- Authority
- MX
- Mexico
- Prior art keywords
- collagenase
- cellulite
- injected
- purified
- treatment
- Prior art date
Links
- 108060005980 Collagenase Proteins 0.000 title claims abstract description 78
- 102000029816 Collagenase Human genes 0.000 title claims abstract description 78
- 229960002424 collagenase Drugs 0.000 title claims abstract description 76
- 208000035484 Cellulite Diseases 0.000 title claims abstract description 37
- 206010049752 Peau d'orange Diseases 0.000 title claims abstract description 37
- 230000036232 cellulite Effects 0.000 title claims abstract description 37
- 238000002347 injection Methods 0.000 claims abstract description 29
- 239000007924 injection Substances 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 26
- 206010007882 Cellulitis Diseases 0.000 claims description 27
- 241000193403 Clostridium Species 0.000 claims description 7
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 108010013295 Microbial collagenase Proteins 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 238000005192 partition Methods 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 230000002934 lysing effect Effects 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 210000000689 upper leg Anatomy 0.000 description 24
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 208000001708 Dupuytren contracture Diseases 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- 210000001217 buttock Anatomy 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 206010033675 panniculitis Diseases 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 206010034464 Periarthritis Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004003 subcutaneous fat Anatomy 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 241000193159 Hathewaya histolytica Species 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- 230000008033 biological extinction Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 208000004362 Penile Induration Diseases 0.000 description 2
- 208000020758 Peyronie disease Diseases 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 239000012931 lyophilized formulation Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 229940100611 topical cream Drugs 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 1
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000010603 frozen shoulder Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229940109990 ruscogenin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/30—Characterized by the absence of a particular group of ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77569006P | 2006-02-22 | 2006-02-22 | |
| US11/703,269 US20070224184A1 (en) | 2006-02-22 | 2007-02-07 | Method for treating cellulite |
| PCT/US2007/004752 WO2007100675A2 (en) | 2006-02-22 | 2007-02-22 | Collagenase for treating cellulite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008010767A true MX2008010767A (es) | 2008-09-01 |
Family
ID=38325147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008010767A MX2008010767A (es) | 2006-02-22 | 2007-02-22 | Metodo para tratar celulitis. |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20070224184A1 (https=) |
| EP (1) | EP1991258B1 (https=) |
| JP (5) | JP5775658B2 (https=) |
| KR (2) | KR20120006063A (https=) |
| AU (1) | AU2007221225B2 (https=) |
| BR (1) | BRPI0708186A2 (https=) |
| CA (1) | CA2643171C (https=) |
| DK (1) | DK1991258T3 (https=) |
| ES (1) | ES2553184T3 (https=) |
| HR (1) | HRP20151182T1 (https=) |
| HU (1) | HUE025918T2 (https=) |
| IL (1) | IL193639A (https=) |
| MX (1) | MX2008010767A (https=) |
| NZ (1) | NZ570642A (https=) |
| PL (1) | PL1991258T3 (https=) |
| PT (1) | PT1991258E (https=) |
| RS (1) | RS54372B1 (https=) |
| SI (1) | SI1991258T1 (https=) |
| WO (1) | WO2007100675A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6958150B2 (en) | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
| CN101107006B (zh) * | 2005-01-21 | 2013-09-11 | 纽约州立大学研究基金会 | 治疗黏连性关节囊炎的方法 |
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| WO2008008468A2 (en) * | 2006-07-14 | 2008-01-17 | Duncan Diane I | Compositions and methods for fat reduction |
| US10071143B1 (en) | 2007-05-03 | 2018-09-11 | The Research Foundation For The State University Of New York | Methods for non-surgical treatment of carpal tunnel syndrome |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| EP2403523A1 (en) * | 2009-03-06 | 2012-01-11 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof |
| JP5284239B2 (ja) * | 2009-10-07 | 2013-09-11 | 株式会社メタコ | スクリーン装置 |
| FR2966734B1 (fr) | 2010-10-29 | 2014-07-18 | Max Rombi | Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides |
| JP2014530873A (ja) * | 2011-10-21 | 2014-11-20 | オーキシリウム インターナショナル ホールディングス，インコーポレイテッド | Ｅｆｐの治療または低減方法 |
| PT2802652T (pt) | 2012-01-12 | 2019-09-10 | Endo Global Ventures | Enzimas de clostridium histolyticum |
| US9636385B2 (en) | 2012-10-24 | 2017-05-02 | The Research Foundation For The State University Of New York | Use of collagenase to treat glaucoma |
| US20150196625A9 (en) | 2013-01-07 | 2015-07-16 | Rudolph D. Paladini | Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof |
| EP3834840B8 (en) | 2013-03-15 | 2025-09-17 | Endo Biologics Limited | Treatment method and product for uterine fibroids using purified collagenase |
| US10117892B2 (en) | 2013-08-29 | 2018-11-06 | Allergan, Inc. | Devices and methods for reducing the appearance of cellulite |
| CN103751102A (zh) | 2014-01-15 | 2014-04-30 | 上海交通大学 | 一种胶原酶温敏水凝胶及其制备方法和应用 |
| EP4591945A3 (en) * | 2017-03-01 | 2026-04-15 | Endo Operations Limited | Apparatus and method for assessing and treating cellulite |
| JP7227918B2 (ja) | 2017-03-28 | 2023-02-22 | エンド ベンチャーズ リミテッド | コラゲナーゼ産生の改良された方法 |
| WO2020021332A2 (en) * | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
| WO2020021330A2 (en) * | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
| US20240277595A1 (en) * | 2018-09-18 | 2024-08-22 | Endo Global Aesthetics Limited | Compositions and methods for treating cellulite |
| US20220305094A1 (en) * | 2019-01-06 | 2022-09-29 | Endo Global Aesthetics Limited | Collagenase formulations and methods of producing the same |
| US11872267B2 (en) | 2019-10-15 | 2024-01-16 | The Johns Hopkins University | Treatment of uterine fibroids using purified collagenase |
| WO2021108751A1 (en) * | 2019-11-26 | 2021-06-03 | Standard Of Care Corporation | Hyaluronidase compositions and methods of using same to treat cellulite |
| CA3252851A1 (en) * | 2022-05-10 | 2023-11-16 | Endo Global Aesthetics Limited | Collagenase-mediated methods for reducing bruising in a subject with cellulite |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338300A (en) * | 1981-02-05 | 1982-07-06 | The Regents Of The University Of California | Use of purified clostridial collangenase in the treatment of Peyronie's disease |
| US4524065A (en) * | 1983-08-04 | 1985-06-18 | Bio-Specifics N.V. | Method for the prevention and treatment of scars with enzymes |
| US4645668A (en) * | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
| US5393792A (en) * | 1991-11-20 | 1995-02-28 | Advance Biofactures Of Curacao, N.V. | High dosage topical forms of collagenase |
| US5332503A (en) * | 1993-04-16 | 1994-07-26 | Baxter International Inc. | Process for purifying collagenase |
| CA2189646C (en) * | 1994-06-24 | 1999-05-25 | Francis E. Dwulet | A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum |
| US5589171A (en) * | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
| CA2158822C (en) * | 1994-09-27 | 2008-12-23 | Kusuki Nishioka | Therapeutic agent for rheumatic disease |
| US6958150B2 (en) * | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
| US5830741A (en) * | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
| US6086872A (en) * | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
| US6335388B1 (en) * | 1997-10-03 | 2002-01-01 | Lavipharm Laboratories Inc. | Prolamine-plant polar lipid composition, its method of preparation and applications thereof |
| US6022539A (en) * | 1999-06-03 | 2000-02-08 | Advance Biofactures Of Curacao | Amelioration of peyronie's disease |
| US6358539B1 (en) * | 1999-08-20 | 2002-03-19 | Howard Murad | Pharmaceutical compositions for reducing the appearance of cellulite |
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| CN101107006B (zh) * | 2005-01-21 | 2013-09-11 | 纽约州立大学研究基金会 | 治疗黏连性关节囊炎的方法 |
| US7811560B2 (en) * | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
| US20210169844A1 (en) * | 2019-12-10 | 2021-06-10 | Tulex Pharmaceuticals Inc. | Compositions and methods for treating epilepsy, seizures and other conditions |
-
2007
- 2007-02-07 US US11/703,269 patent/US20070224184A1/en not_active Abandoned
- 2007-02-22 AU AU2007221225A patent/AU2007221225B2/en active Active
- 2007-02-22 ES ES07751508.8T patent/ES2553184T3/es active Active
- 2007-02-22 SI SI200731702T patent/SI1991258T1/sl unknown
- 2007-02-22 PT PT77515088T patent/PT1991258E/pt unknown
- 2007-02-22 PL PL07751508T patent/PL1991258T3/pl unknown
- 2007-02-22 MX MX2008010767A patent/MX2008010767A/es active IP Right Grant
- 2007-02-22 HU HUE07751508A patent/HUE025918T2/en unknown
- 2007-02-22 EP EP07751508.8A patent/EP1991258B1/en active Active
- 2007-02-22 CA CA2643171A patent/CA2643171C/en active Active
- 2007-02-22 RS RS20150714A patent/RS54372B1/sr unknown
- 2007-02-22 WO PCT/US2007/004752 patent/WO2007100675A2/en not_active Ceased
- 2007-02-22 KR KR1020117028099A patent/KR20120006063A/ko not_active Ceased
- 2007-02-22 NZ NZ570642A patent/NZ570642A/en unknown
- 2007-02-22 HR HRP20151182TT patent/HRP20151182T1/hr unknown
- 2007-02-22 JP JP2008556445A patent/JP5775658B2/ja active Active
- 2007-02-22 DK DK07751508.8T patent/DK1991258T3/en active
- 2007-02-22 KR KR1020087022877A patent/KR20080108996A/ko not_active Ceased
- 2007-02-22 BR BRPI0708186-3A patent/BRPI0708186A2/pt not_active Application Discontinuation
-
2008
- 2008-08-21 IL IL193639A patent/IL193639A/en active IP Right Grant
-
2015
- 2015-05-08 JP JP2015095704A patent/JP2015134840A/ja active Pending
-
2016
- 2016-06-03 US US15/173,092 patent/US10123959B2/en active Active
- 2016-09-14 JP JP2016179732A patent/JP6498167B2/ja active Active
-
2018
- 2018-09-27 JP JP2018182242A patent/JP6649449B2/ja active Active
- 2018-10-19 US US16/165,910 patent/US20190053995A1/en not_active Abandoned
-
2019
- 2019-11-05 JP JP2019200656A patent/JP6853331B2/ja active Active
-
2022
- 2022-04-22 US US17/727,118 patent/US20220249348A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220249348A1 (en) | Methods for treating cellulite | |
| US4524065A (en) | Method for the prevention and treatment of scars with enzymes | |
| US7854929B2 (en) | Method for treating lateral epicondylitis using collagenase | |
| CN100546648C (zh) | 经皮肉毒杆菌毒素组合物 | |
| US5589171A (en) | Treatment of Dupuytren's disease with collagenase | |
| US6086872A (en) | Amelioration of dupuytren's disease | |
| MX2014004792A (es) | Metodo de tratamiento o reduccion de efp. | |
| US20100029566A1 (en) | Use of at least one botulinum neurotoxin for treating the pain induced by therapeutic treatments for the aids virus | |
| WO2007100590A2 (en) | Methods for treating cellulite | |
| EP3137102B1 (en) | Apc for use in the treatment of abnormal cutaneous scarring | |
| EP2480250A1 (en) | Method of treating osteoporosis with a neurotoxin | |
| JP2020100648A (ja) | 創傷治癒に対するａｐｃ類似体の使用 | |
| US9636385B2 (en) | Use of collagenase to treat glaucoma | |
| JP2025530779A (ja) | 増加された効能および効果持続をともなう神経毒素組成物。 | |
| US10071143B1 (en) | Methods for non-surgical treatment of carpal tunnel syndrome | |
| HK1235306B (zh) | 治疗异常皮肤瘢痕形成 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |